CL2022002015A1 - Tratamiento del carcinoma corticosuprarrenal con moduladores selectivos de receptores de glucocorticoides (sgrm) e inhibidores - Google Patents

Tratamiento del carcinoma corticosuprarrenal con moduladores selectivos de receptores de glucocorticoides (sgrm) e inhibidores

Info

Publication number
CL2022002015A1
CL2022002015A1 CL2022002015A CL2022002015A CL2022002015A1 CL 2022002015 A1 CL2022002015 A1 CL 2022002015A1 CL 2022002015 A CL2022002015 A CL 2022002015A CL 2022002015 A CL2022002015 A CL 2022002015A CL 2022002015 A1 CL2022002015 A1 CL 2022002015A1
Authority
CL
Chile
Prior art keywords
glucocorticoid receptor
cell
grm
adrenocortical carcinoma
sgrms
Prior art date
Application number
CL2022002015A
Other languages
English (en)
Inventor
Greeenstein Andrew
Grauer Andreas
Shepherd Stacie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CL2022002015A1 publication Critical patent/CL2022002015A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulgan métodos y composiciones para tratar a un sujeto que padece carcinoma corticosuprarrenal y que tiene exceso de cortisol. Los métodos brindan beneficios terapéuticos que incluyen la reducción de la carga tumoral del ACC, la restauración de las vías de señalización de linfocitos T y linfocitos (NK), el aumento en la infiltración de linfocitos T y NK en el tumor de ACC, la reducción de la infiltración de neutrófilos en el tumor de ACC en el paciente y otros beneficios terapéuticos. Los métodos incluyen la administración de un modulador de receptor de glucocorticoide (GRM) (que puede ser un modulador selectivo de receptor de glucocorticoide (SGRM)) y un inhibidor de control de anticuerpos. En algunas realizaciones, el GRM (por ejemplo, un SGRM) se administra por vía oral. El GRM puede ser un compuesto no esteroide que comprende: una estructura de azadecalina fusionada; una estructura de azadecalina de heteroaril cetona fusionada; o una estructura de azadecalina octahidro fusionada.
CL2022002015A 2020-01-29 2022-07-26 Tratamiento del carcinoma corticosuprarrenal con moduladores selectivos de receptores de glucocorticoides (sgrm) e inhibidores CL2022002015A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062967517P 2020-01-29 2020-01-29
US202063040941P 2020-06-18 2020-06-18
US202063125630P 2020-12-15 2020-12-15

Publications (1)

Publication Number Publication Date
CL2022002015A1 true CL2022002015A1 (es) 2023-01-20

Family

ID=77079925

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002015A CL2022002015A1 (es) 2020-01-29 2022-07-26 Tratamiento del carcinoma corticosuprarrenal con moduladores selectivos de receptores de glucocorticoides (sgrm) e inhibidores

Country Status (13)

Country Link
US (1) US20230053364A1 (es)
EP (1) EP4096663A4 (es)
JP (1) JP2023516885A (es)
KR (1) KR20220133275A (es)
CN (1) CN115361952A (es)
AU (1) AU2021214938B2 (es)
BR (1) BR112022015011A2 (es)
CA (1) CA3165708A1 (es)
CL (1) CL2022002015A1 (es)
IL (1) IL294862A (es)
MX (1) MX2022009315A (es)
WO (1) WO2021154750A1 (es)
ZA (1) ZA202207893B (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4851345B2 (ja) * 2004-01-09 2012-01-11 コーセプト セラピューティクス， インコーポレイテッド アザデカリン糖質コルチコイド受容体モジュレーター
EP3423453A4 (en) * 2016-03-01 2019-11-06 Corcept Therapeutics, Inc. USE OF GLUCOCORTICOID RECEPTOR MODULATORS TO POTENTIATE CONTROL POINT INHIBITORS

Also Published As

Publication number Publication date
MX2022009315A (es) 2022-08-22
ZA202207893B (en) 2023-12-20
CA3165708A1 (en) 2021-08-05
KR20220133275A (ko) 2022-10-04
WO2021154750A1 (en) 2021-08-05
JP2023516885A (ja) 2023-04-21
EP4096663A4 (en) 2023-10-25
AU2021214938A1 (en) 2022-09-08
IL294862A (en) 2022-09-01
BR112022015011A2 (pt) 2022-09-20
AU2021214938B2 (en) 2024-02-08
CN115361952A (zh) 2022-11-18
EP4096663A1 (en) 2022-12-07
US20230053364A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
Ganguly et al. Melatonin promotes angiogenesis during protection and healing of indomethacin‐induced gastric ulcer: role of matrix metaloproteinase‐2
Lin et al. Melatonin inhibits MMP‐9 transactivation and renal cell carcinoma metastasis by suppressing Akt‐MAPK s pathway and NF‐κB DNA‐binding activity
Hunt et al. Potassium-competitive acid blockers (P-CABs): are they finally ready for prime time in acid-related disease?
Zhang et al. Cisplatin treatment increases stemness through upregulation of hypoxia‐inducible factors by interleukin‐6 in non‐small cell lung cancer
Caliceti et al. 17β-estradiol enhances signalling mediated by VEGF-A-delta-like ligand 4-notch1 axis in human endothelial cells
BR112019004322A2 (pt) moduladores de receptor glicocorticoide para tratar câncer pancreático
Bennardo et al. Autologous platelet‐rich fibrin injections in the management of facial cutaneous sinus tracts secondary to medication‐related osteonecrosis of the jaw
Yu et al. Bradykinin enhances cell migration in human prostate cancer cells through B2 receptor/PKCδ/c‐Src dependent signaling pathway
Horwich et al. A pilot study of intermittent androgen deprivation in advanced prostate cancer
Tomita et al. Angiosarcoma of the scalp successfully treated with pazopanib
CL2020002465A1 (es) Método de tratamiento de enfermedad fibrótica
CO6460746A2 (es) Tratamiento de trastornos cognitivos con determinados receptores de ácido nicotínico alfa-7 en combinación con inhibidores de acetilcolinesterasa
NI201800127A (es) Composiciones antineoplásicas
Hong et al. Impending skin necrosis after dermal filler injection: A “golden time” for first‐aid intervention
Katsinelos et al. Aggressive treatment of acute anal fissure with 0.5% nifedipine ointment prevents its evolution to chronicity
CL2021002646A1 (es) Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicosactivos
UY38912A (es) Inhibidores del factor d del complemento para administración oral
BR112021021826A2 (pt) Terapias de combinação compreendendo os inibidores de apremilast e tyk2
CL2021001528A1 (es) Formulaciones farmacéuticas que contienen relacorilant, un compuesto heteroaril-cetona azadecalina fusionada.
Medina et al. Somatostatin analogues in the prevention of pancreas‐related complications after pancreatic resection
Madeddu et al. Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine‑dependent breast cancer: A report of two cases
Arda et al. Medical expulsive therapy for distal ureteral stones: Tamsulosin versus silodosin in the Turkish population
CL2022002015A1 (es) Tratamiento del carcinoma corticosuprarrenal con moduladores selectivos de receptores de glucocorticoides (sgrm) e inhibidores
CO2022005926A2 (es) Inhibidores del factor d del complemento para administración oral
Mahmoodi et al. The comparison of the effects of silybin and silybin-phosphatidylcholine on viability and ESR expression in human breast cancer T47D cell line